Johnson & Johnson Settles Lawsuits for $5.5 Billion
On Monday, Johnson & Johnson announced plans to pay around $5.5 billion to resolve numerous lawsuits asserting that its baby powder and other talc products could lead to ovarian cancer. This marks a significant resolution that might bring a decade-long legal dispute to an end.
The settlement is said to cover approximately 76,000 claims, including a significant case consolidated in New Jersey’s federal court as well as associated lawsuits in state courts. This agreement represents nearly all of the pending talc-related claims against the company. Previously, J&J had reached settlements for most lawsuits related to allegations of asbestos in its talc, which were claimed to cause mesothelioma.
A law firm representing the plaintiffs confirmed the settlement, labeling it as a beneficial resolution after years of fighting in court. However, for the deal to be finalized, it requires acceptance from 95% of those claiming ovarian cancer in both state and federal jurisdictions.
Eric Haas, the vice president of litigation for J&J, asserted that the allegations lacked merit but acknowledged the company’s decision to settle in order to move past the litigation.
“We believe we would win in future litigations, as has often been demonstrated, but this agreement gives us the chance to focus on creating life-saving products,” Haas remarked.
The payment plan includes $3 billion in 2027 and additional sums in 2028. However, should more individuals participate in the settlement, the total payout may exceed this initial estimate.
Chris Seger, an attorney who has represented around 2,500 clients concerning talc claims, indicated that J&J’s payments could surpass $7 billion. He noted that the settlement designates funds specifically for eligible ovarian cancer claims, yet does not limit the overall amount they might end up paying.
“I believe this settlement is fair, and I think our clients will be pleased with the outcome,” Seger explained.
The Deal’s Future Depends on Court Confirmation
The settlement comes on the heels of a series of legal victories for J&J, including positive outcomes in individual cases and successful attempts to prevent certain plaintiffs’ attorneys from participating in the trials.
Recently, J&J achieved a crucial legal win when a federal judge questioned the plaintiffs’ ability to definitively prove that talc is linked to ovarian cancer.
J&J has consistently denied that its talc products cause cancer, insisting its talc is safe and free from asbestos. The company discontinued its talc-based baby powder sales in the U.S. back in 2020, transitioning to cornstarch alternatives.
The legal case was reinitiated in March 2025 after a lengthy hiatus during which the company attempted three bankruptcies through subsidiary companies, aiming for a strategy known as the “Texas Two Step.” Each bankruptcy attempt was ultimately dismissed.
Prior to these bankruptcy efforts, J&J had a varied history in talc-related cases, winning substantial verdicts for 22 women who claimed its baby powder contributed to their ovarian cancer development. While J&J successfully defended some cases, others saw their judgments considerably reduced on appeal.
In contrast to the previously proposed bankruptcy settlement, the current agreement only pertains to existing claims and doesn’t provide for future litigation. Seger noted that excluding future claims allows for a quicker payout to current plaintiffs, ensuring that claims will be resolved in 18 months instead of a decade.
